Synthesis of adjustable {312}/{004} facet heterojunction MWCNTs/Bi5O7I photocatalyst for ofloxacin degradation: Novel insights into the charge carriers transport.

Multi-wall carbon nanotubes (MWCNTs) with high electrical conductivity are commonly accounted as the ideal additives to enhance the charge surface migration efficiency in photocatalysis. Theoretically, the MWCNTs-modified binary photocatalysts have potential for the change of nanocrystal structure. Herein, we reports an adjustable {312}/{004}facet heterojunction MWCNTs/Bi5O7I nanocomposite. Interestingly, the synergistic effect of {312}/{004}facet heterojunction and MWCNTs can effectively accelerate the spatial charge carriers transport. A novel {312}/{004}facet "S-scheme" pathway was proven to be the dominated pathway for the enhancement of spatial charge carriers. As a result, the MWCNTs-{312}/{004}Bi5O7I composites exhibited superior photocatalytic oxidation efficiency for a representative antibiotics ofloxacin photodegradation. Density functional theory (DFT) calculation and LC-MS/MS analysis confirmed that the possible dealkylation and oxidation pathways could be found in OFL degradation. This work provides novel insights for the relationship between charge carrier transport and facet structure-property.

A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.

BACKGROUND: Sorafenib is the standard first-line therapy for hepatocellular carcinoma (HCC) and probably ectopic hepatocellular carcinoma (EHCC) as well. No report involves a side effect of delayed high fever of sorafenib. This manuscript describes a case of EHCC in the thoracic and abdominal cavities, who showed a delayed high fever and maculopapules during sorafenib treatment. CASE PRESENTATION: The patient is a 63-year-old Chinese male with advanced EHCC, taking sorafenib 400 mg twice daily. On the tenth day, red maculopapules appeared all over the body. On the same day, the patient began to suffer from continuous high fever. Due to these effects, the patient was asked to cease sorafenib treatment, and the high fever and maculopapules were alleviated quickly. However, the symptoms were present again upon re-challenge of sorafenib. Prednisone was then administered to control the symptoms, with the dosage gradually reduced from 30 to 5 mg/day in 1.5 months. No recurrence of fever or maculopapules has been found. Tumor response reached partial response (PR) and progression free survival (PFS) reached 392 days + by the date of Apr. 14th, 2016. CONCLUSION: EHCC could be treated like orthotopic HCC by oral administration of sorafenib, which shows good tumor response and survival benefit. Delayed high fever and maculopapules are potential, rare and severe side effects of sorafenib, and could be effectively controlled by glucocorticoid.